Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.

Autor: Almekinders MM; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pathology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., Bismeijer T; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands., Kumar T; Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA.; Department of Genetics, MD Anderson Cancer Center, Houston, TX, USA.; MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, TX, USA., Yang F; Department of Translational Molecular Pathology, MD Anderson Cancer Center, Houston, TX, USA., Thijssen B; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Linden R; Department of Pathology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van Rooijen C; Department of Pathology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Vonk S; Department of Pathology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Sun B; Department of Translational Molecular Pathology, MD Anderson Cancer Center, Houston, TX, USA., Parra Cuentas ER; Department of Translational Molecular Pathology, MD Anderson Cancer Center, Houston, TX, USA., Wistuba II; Department of Translational Molecular Pathology, MD Anderson Cancer Center, Houston, TX, USA., Krishnamurthy S; Department of Pathology, MD Anderson Cancer Center, Houston, TX, USA., Visser LL; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Seignette IM; Department of Pathology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Hofland I; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Sanders J; Department of Pathology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Broeks A; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Love JK; Breast Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA., Menegaz B; Department of Surgery, Baylor College of Medicine, Houston, TX, USA., Wessels L; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Thompson AM; Division of Surgical Oncology, Baylor College of Medicine, Houston, TX, USA., de Visser KE; Oncode Institute, Utrecht, The Netherlands.; Division of Tumour Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., Hooijberg E; Department of Pathology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Lips E; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Futreal A; Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA., Wesseling J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. j.wesseling@nki.nl.; Department of Pathology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. j.wesseling@nki.nl.; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. j.wesseling@nki.nl.
Jazyk: angličtina
Zdroj: British journal of cancer [Br J Cancer] 2022 Oct; Vol. 127 (7), pp. 1201-1213. Date of Electronic Publication: 2022 Jun 29.
DOI: 10.1038/s41416-022-01888-2
Abstrakt: Background: Ductal carcinoma in situ (DCIS) is treated to prevent subsequent ipsilateral invasive breast cancer (iIBC). However, many DCIS lesions will never become invasive. To prevent overtreatment, we need to distinguish harmless from potentially hazardous DCIS. We investigated whether the immune microenvironment (IME) in DCIS correlates with transition to iIBC.
Methods: Patients were derived from a Dutch population-based cohort of 10,090 women with pure DCIS with a median follow-up time of 12 years. Density, composition and proximity to the closest DCIS cell of CD20 + B-cells, CD3 + CD8 + T-cells, CD3 + CD8 - T-cells, CD3 + FOXP3 + regulatory T-cells, CD68 + cells, and CD8 + Ki67 + T-cells was assessed with multiplex immunofluorescence (mIF) with digital whole-slide analysis and compared between primary DCIS lesions of 77 women with subsequent iIBC (cases) and 64 without (controls).
Results: Higher stromal density of analysed immune cell subsets was significantly associated with higher grade, ER negativity, HER-2 positivity, Ki67 ≥ 14%, periductal fibrosis and comedonecrosis (P < 0.05). Density, composition and proximity to the closest DCIS cell of all analysed immune cell subsets did not differ between cases and controls.
Conclusion: IME features analysed by mIF in 141 patients from a well-annotated cohort of pure DCIS with long-term follow-up are no predictors of subsequent iIBC, but do correlate with other factors (grade, ER, HER2 status, Ki-67) known to be associated with invasive recurrences.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: